Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and

Trial Details

NCT ID
NCT05312801
Phase
PHASE1
Sponsor
Luminary Therapeutics
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • BAFF CAR-T
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Subjects must have histologically confirmed non-Hodgkin lymphoma relapsed after 2 or more lines of therapy or disease refractory to chemotherapy (d…
  • No evidence of central nervous system (CNS) lymphoma.
  • Male or female \> 18 years of age.
  • Eastern Cooperative Oncology Group Performance status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →